Table 3 Results of other recent chemoradiation trials, unresectable stage III (without cetuximab)
From: A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer
| Author, patient number | Treatment | Median survival (PFS) |
|---|---|---|
| Bepler et al. [41], 39 | 2 cycles induction carboplatin and gemcitabine, RT up to 74 Gy (mean 70) with weekly carboplatin and paclitaxel |
22.7 mo (14.3 mo) |
| Socinski et al. [42], 43 | 2 cycles induction carboplatin and paclitaxel, RT 74 Gy with weekly carboplatin and paclitaxel | 24.3 mo |
| Krzakowski et al. [43], 54 | 2 cycles induction cisplatin and vinorelbine, RT 66 Gy with 2 cycles cisplatin and vinorelbine |
23.4 mo (12.5 mo) |
| Sejpal et al. [44], 62 | Weekly carboplatin and paclitaxel, RT median 74 Gy with protons | 24.4 mo |
| Segawa et al. [45], 99 | RT 60 Gy with 4 cycles of concomitant cisplatin and docetaxel |
26.8 mo (13.4 mo) |
| Cho et al. [46], 49 | Weekly carboplatin and paclitaxel, RT 60 Gy in 25 fractions |
28.1 mo (13.7 mo) |
| Gandara et al. [47], 83 | RT 61 Gy with 2 cycles of concomitant cisplatin and etoposide, consolidation docetaxel |
26 mo (16 mo) |